Overview

• A Nature Medicine paper reports that BioMapAI analyzed stool, blood and clinical tests from 249 participants to distinguish ME/CFS patients with 90% accuracy.
• Patients with chronic fatigue syndrome showed markedly reduced levels of butyrate and other gut-derived metabolites vital for energy production and inflammation control.
• Immune cell profiling emerged as the strongest predictor of overall symptom severity, whereas microbiome measures closely tracked emotional distress and sleep disturbances.
• The identification of objective biomarkers could shift ME/CFS diagnosis away from exclusion-based methods and lay the groundwork for personalized interventions.
• Shared microbial and immune signatures between ME/CFS and long Covid highlight overlapping mechanisms and point to broader applications for multi-omics diagnostic platforms.